Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $15.57
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has earned an average recommendation of “Buy” from the seven ratings firms that are currently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued ratings on the stock in the […]
More Stories
Top 10 Investment Accounting Software & Other Related Software
Managing complex investment portfolios can be hectic most of the time, as a small mistake can lead to a huge...
Top 10 Richest K-Pop Idols in 2026
Do you also like K-pop or Korean pop? Then this article is for you. Let’s start. In this blog, you...
Over-the-Counter Medicines, Other Items Recalled Over Feces Contamination: FDA
By Jack Phillips The U.S. Food and Drug Administration (FDA) late last week announced that a distributor is recalling its...
Iranian President Says His Country in ‘Full-Fledged War’ With US, Europe, and Israel
By Jack Phillips Iranian President Masoud Pezeshkian said Saturday that the Iranian regime is in a full-scale war with the...
US Airline Industry Caps a Strong 2025—What Lies Ahead in 2026
By Panos Mourdoukoutas Despite a shaky start earlier in the year, U.S. airline travel reached another milestone during the 2025...
What Trump’s National Security Strategy Means for Canada
By Noe Chartier Canada receives but a passing mention in the recently released U.S. National Security Strategy, but that doesn’t...